Clinical Scorecard: Plasma pTau217 Cutoffs for Clinical Use
At a Glance
| Category | Detail |
|---|---|
| Condition | Alzheimer's Disease Diagnosis |
| Key Mechanisms | Elevated plasma pTau217 levels due to kidney dysfunction and anemia affect diagnostic accuracy. |
| Target Population | Patients with cognitive impairment, including mild cognitive impairment and dementia of Alzheimer type. |
| Care Setting | Multicenter clinical evaluations with PET imaging. |
Key Highlights
- Subgroup-specific plasma pTau217 cutoffs improve diagnostic accuracy.
- Double-cutoff strategy yields intermediate results in 39% of cases.
- Optimal cutoffs enhance cost efficiency in chronic kidney disease and anemia.
Guideline-Based Recommendations
Diagnosis
- Utilize subgroup-specific optimal cutoffs adjusted for kidney function, BMI, and anemia.
Management
- Consider confirmatory imaging for intermediate results from double-cutoff strategy.
Monitoring & Follow-up
- Regular assessment of plasma pTau217 levels in patients with kidney dysfunction and anemia.
Risks
- Increased false classifications without adjusted cutoffs, leading to unnecessary costs.
Patient & Prescribing Data
Cognitively unimpaired individuals, patients with mild cognitive impairment, and patients with dementia.
Adjust diagnostic thresholds for plasma pTau217 based on kidney function and anemia status.
Clinical Best Practices
- Implement biologically informed approaches for plasma pTau217 testing.
- Conduct external validation in diverse populations to enhance generalizability.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
